Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cardiovascular Diseases: full-pipeline trial registry
134 of 304 indexed Cardiovascular Diseases trials are currently recruiting.
Corpus placement: #27 of 28,707 conditions by registered trial count.
304 US clinical trials · 134 currently recruiting · #27 of 28,707 conditions by registered trial count
Cardiovascular Diseases: 304 US clinical trials tracked, 134 recruiting.
Cardiovascular Diseases is the subject of 304 registered US clinical trials on ClinicalTrials.gov, 134 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is Duke University, running 10 of these trials.
Enrollment posture brief
Registry condition cardiovascular-diseases
OPEN 134 | RECR 44% | LATE 26 | EARLY 28 | RANK #27 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Suicide (44% recruiting · 93 trials)
Cardiovascular Diseases lists 134 open slots (44% of 304 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cardiovascular Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cardiovascular Diseases is recruiting above its size-band peers.
134 of 304 indexed trials (44.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cardiovascular Diseases trials is spread across many organizations.
Duke University accounts for 10 of 304 trials (3.3%). 159 distinct sponsors appear on at least one study for this condition label.
-
Typical Cardiovascular Diseases enrolment sits around 200 participants.
Median target enrolment is 200 among the 301 trials that report a genuine target (sentinel values excluded). 101 of those (33.6%) plan for fewer than 100 participants.
-
Cardiovascular Diseases research is mostly interventional.
225 interventional and 79 observational studies make up this index (74% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
304 total, page 4 of 7
Integrating Abbott Point-of-Care Technologies and the Community Scientist Model to Support HbA1c Testing Per ADA
Sansum Diabetes Research Institute
NCT05000840
A Pragmatic Trial of Chronic Disease Approaches to Ameliorate Tobacco Related Cardiovascular Disease Health Disparities
University of Minnesota
NCT05671380
Clinical Markers of Dysphagia in Cardiac Surgical Patients
University of Florida
NCT05304416
CommunityRx-Cardiovascular Disease
University of North Carolina, Chapel Hill
NCT06264726
RADIANCE Continued Access Protocol
ReCor Medical
NCT05017935
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
atHeart Medical
NCT04591392
2019-06 TRISCEND Study
Edwards Lifesciences
NCT04221490
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
ReCor Medical
NCT03614260
Enhancing Rural Health Via Cardiovascular Telehealth for Rural Patients Implementation (E-VICTORS)
Wake Forest University Health Sciences
NCT04617834
Behavioral Chronotype: Impact on Sleep and Metabolism
University of Chicago
NCT03647306
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT05078190
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Abramson Cancer Center at Penn Medicine
NCT05096338
Collaborate and Leverage Evidence in African American Rural Network
University of North Carolina, Chapel Hill
NCT06730633
A Study of Mosliciguat in PH-ILD
Pulmovant
NCT06635850
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
Inquis Medical
NCT05907564
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03520660
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
University of Rochester
NCT04922281
Cancer Survivor Cardiomyopathy Detection
Mayo Clinic
NCT05201014
Mindfulness App Training for Cardiovascular Health
University of Pittsburgh
NCT06152185
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Abbott Medical Devices
NCT03433274
Team-based Care to Improve Hypertension
New York University
NCT05413252
Re-thinking the Role of Peers And Training Patients [RePeAT]
University of Rochester
NCT05933655
Effects of Dark Chocolate on the Risk Factors of Cardiovascular Diseases
San Diego State University
NCT06808282
Estrogen and Microvascular Function
Medical College of Wisconsin
NCT06043310
Dietary Approaches for Cardiovascular Health Study
University of Delaware
NCT05180435
Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome
Rutgers, The State University of New Jersey
NCT06461273
Watermelon Dose Response Blood Pressure Study
Clinical Nutrition Research Center, Illinois Institute of Technology
NCT05892328
Response of Cardiometabolic Biomarkers and Gut Microbiota to Walnut Consumption
University of California, Davis
NCT05321277
Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial
Dana-Farber Cancer Institute
NCT07442578
Enhancing Mental and Physical Health of Women Veterans
VA Office of Research and Development
NCT05050266
AB-1002 in Patients With Class III Heart Failure
AskBio
NCT04179643
Circadian Rhythm Disruption in the Hospital Intensive Care Environment
University of Pennsylvania
NCT05828680
A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation
Boston Scientific Corporation
NCT04147884
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen Research & Development
NCT03492580
Evaluation of VLER-Indiana Health Information Exchange Demonstration Project
VA Office of Research and Development
NCT01446705
Active Choice in the EHR to Promote Statin Therapy
University of Pennsylvania
NCT03271931
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
National Heart, Lung, and Blood Institute (NHLBI)
NCT00000620
Raloxifene Use for The Heart
Eli Lilly and Company
NCT00190593
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications
University of Colorado, Denver
NCT03973931
Cooking for Health Optimization With Patients
Tulane University
NCT03443635
Home Use of Automatic External Defibrillators to Treat Sudden Cardiac Arrest
National Heart, Lung, and Blood Institute (NHLBI)
NCT00047411
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
NYU Langone Health
NCT01471522
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
CardioDx
NCT00500617
Virtual World-Based Cardiac Rehabilitation
Mayo Clinic
NCT05897710
Understanding the Genetic and Hereditary Basis of Atherosclerosis
Wake Forest University Health Sciences
NCT00344292
Occluded Artery Trial (OAT)
NYU Langone Health
NCT00004562
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
Duke University
NCT00023595
Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])
Northwestern University
NCT00626379
A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease
Duke University
NCT03936660
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit
Geisinger Clinic
NCT03470701
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 18 |
| Phase 3 | 13 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Cardiovascular Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cardiovascular Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cardiovascular Diseases page
304 registered trials, 134 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 134 Cardiovascular Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Duke University sponsors the most Cardiovascular Diseases trials on record, review their full trial history before evaluating a specific study. See Duke University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cardiovascular Diseases condition card totals 304 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.